184 related articles for article (PubMed ID: 37315262)
1. Venetoclax and Azacitidine in the Treatment of
Ma J; Morimoto K; Pulsipher MA; Parekh C
JCO Precis Oncol; 2023 Jun; 7():e2200693. PubMed ID: 37315262
[No Abstract] [Full Text] [Related]
2. Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient.
Niscola P; Mazzone C; Fratoni S; Ardu NR; Cesini L; Giovannini M; Ottone T; Anemona L; Voso MT; de Fabritiis P
Acta Haematol; 2023; 146(5):408-412. PubMed ID: 37231772
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
Ding H; Hashem H; Cabral L; Rangarajan H; Abusin G; Lazarus HM; Abu-Arja R
Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 27976488
[TBL] [Abstract][Full Text] [Related]
4. Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Oya S; Ozawa H; Maehiro Y; Nakamura T; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Leuk Res; 2023 Jul; 130():107313. PubMed ID: 37207502
[No Abstract] [Full Text] [Related]
5. Treatment With Azacitidine in the Context of Palliative Care for a Patient With Acute Myeloid Leukemia Complicating Fanconi Anemia With Biallelic FANCD1/BRCA 2 Mutations.
Berot A; Pluchart C
J Pediatr Hematol Oncol; 2018 Apr; 40(3):247-248. PubMed ID: 29389832
[No Abstract] [Full Text] [Related]
6. [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
Liu XH; Wu Y; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):166. PubMed ID: 35381683
[No Abstract] [Full Text] [Related]
7. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
Sockel K; Wermke M; Radke J; Kiani A; Schaich M; Bornhäuser M; Ehninger G; Thiede C; Platzbecker U
Haematologica; 2011 Oct; 96(10):1568-70. PubMed ID: 21750085
[No Abstract] [Full Text] [Related]
9. [Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].
Sun L; Ye SJ; Zhou N; Han XZ; Qi JX; Liu XJ; Luo JM; Yang L
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):826-832. PubMed ID: 36709196
[No Abstract] [Full Text] [Related]
10. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sartor C; Brunetti L; Audisio E; Cignetti A; Zannoni L; Cristiano G; Nanni J; Ciruolo R; Zingarelli F; Ottaviani E; Patuelli A; Bandini L; Forte D; Sciabolacci S; Cardinali V; Papayannidis C; Cavo M; Martelli MP; Curti A
Br J Haematol; 2023 Aug; 202(3):599-607. PubMed ID: 37226312
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
Wermke M; Thiede C; Kiani A; Ehninger G; Bornhäuser M; Platzbecker U
Leukemia; 2010 Jan; 24(1):236-7. PubMed ID: 19776758
[No Abstract] [Full Text] [Related]
12. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
Tsuzuki H; Kawase T; Nakazawa T; Mori M; Yoshida T
Oncotarget; 2022 Dec; 13():1359-1368. PubMed ID: 36537913
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
14. Fanconi anemia A protein participates in nucleolar homeostasis maintenance and ribosome biogenesis.
Gueiderikh A; Maczkowiak-Chartois F; Rouvet G; Souquère-Besse S; Apcher S; Diaz JJ; Rosselli F
Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33523834
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
[TBL] [Abstract][Full Text] [Related]
16. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
17. Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group.
Faivre L; Guardiola P; Lewis C; Dokal I; Ebell W; Zatterale A; Altay C; Poole J; Stones D; Kwee ML; van Weel-Sipman M; Havenga C; Morgan N; de Winter J; Digweed M; Savoia A; Pronk J; de Ravel T; Jansen S; Joenje H; Gluckman E; Mathew CG
Blood; 2000 Dec; 96(13):4064-70. PubMed ID: 11110674
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
19. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
20. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]